ResMed insiders dump $31M in shares, CEO leads $20M sell spree

ResMed’s insider activity over the last year is defined by a complete absence of purchases and a steady stream of sales that total $30,968,717 across 41 transactions. All six insiders who traded are senior executives, and together they have liquidated roughly 68% of the total insider‑transaction value. The CEO, Michael J. Farrell, is the dominant seller, having executed five separate sales of 8,009 shares each between June and October 2025, each transaction exceeding $2 million and together amounting to $10,799,787. The CFO contributed 11 sales worth $5,686,932, while a director added another $5,099,024 and other C‑suite members sold $105,783. No director or non‑executive insider bought any shares during the period.

The timing of the sales underscores a pattern of regular, sizable disposals rather than isolated events. The most concentrated month was August 2024, when insiders sold $16,147,359, a figure that dwarfs the $753,949 sold in December 2024 and the $1,037,233 sold in May 2026. This August spike coincides with a period when ResMed’s stock was trading near the bottom of its 52‑week range—approximately 6% above the low—and the Relative Strength Index was at 35, indicating oversold conditions. Despite the technical weakness, the market price sits at $204.22, up 1.16% on the day, while the year‑to‑date return remains negative at –15.2%.

Insider selling can often be attributed to routine equity compensation or portfolio diversification, but the scale and concentration of these transactions merit attention. A buy‑sell ratio below 0.2x typically flags heavy selling, and ResMed’s ratio of 0.00x meets that threshold. Moreover, the fact that all sales originated from C‑suite members amplifies the signal, as executive trades carry more weight than those of directors or minor shareholders. The cumulative $20,076,978 sold by the CEO alone represents roughly 65% of the total insider‑transaction value, a proportion that is uncommon in companies where executives retain confidence in the near‑term outlook.

Investors should weigh this persistent insider outflow against the broader market context. While the stock’s low RSI and proximity to its 52‑week low could suggest a buying opportunity, the absence of any insider buying and the relentless executive selling create a countervailing narrative. The market cap of $29.6 billion reflects a sizable enterprise, yet the current insider behavior may signal concerns about future earnings or strategic direction. Until a shift toward insider accumulation emerges, the prevailing data points to a cautious stance on ResMed’s equity.

Overall, the data paints a picture of sustained executive divestment in a stock that appears technically depressed. The lack of any insider purchases, combined with a zero buy‑sell ratio and a CEO‑driven sell total exceeding $20 million, provides a clear metric for market participants to monitor as they assess ResMed’s valuation and forward momentum.